

Bibliography:

- Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *J Clin Med*. 2020;9(4):947.
- Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev*. 2019;35(1):e3070.
- Dungan K, DeSantis A. Glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. UpToDate. Last updated Sep 1, 2021. Accessed October 12, 2021. Available at: https://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?search=glp%20agonist&source=search_result&selectedTitle=2~98&usage_type=default&display_rank=1.
- Frias JP, Wynne AG, Matyjaszek-Matuszek B, et al. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. *Diabetes Obes Metab*. 2019;21(9):2048-57.
- Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2021;12:1-15.
- Jain AB, Ali A, Gorgojo Martínez JJ, et al. Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. *Int J Clin Pract*. 2021; 75(2):e13731.
- Content Authors: Krull and Scheich Last updated: 7/9/24 | Page 5
- Pharmacy Pearls for Prescribers – Diabetes 2 Series
- Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance. *Clin Diabetes*. 2020;38(4):390-402.
- Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2021
- Clinical Resource, Comparison of GLP-1 Agonists. Pharmacist’s Letter/Prescriber’s Letter. August 2019.
- Yao, H. *et al.* (2024) ‘Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis’, *BMJ* [Preprint]. doi:10.1136/bmj-2023-076410.
- Whitley, H.P., Trujillo, J.M. and Neumiller, J.J. (2023) ‘Special report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages’, *Clinical Diabetes*, 41(3), pp. 467–473. doi:10.2337/cd23-0023.
- *Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial* (2024) Novo Nordisk. Available at: <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167028#> (Accessed: 05 April 2024).
- Bergenstal RM. Understanding Continuous Glucose Monitoring Data. 2018 Aug. In: Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington (VA): American Diabetes Association; 2018 Aug. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538967/> doi: 10.2337/db20181-20.
- American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes— 2024. *Diabetes Care* 2024;47(Suppl. 1):S111–S125.

- Schumacher CA, Isaacs D, Collier I, Klinkebiel D. Use of continuous glucose monitoring to improve glycemic management: A clinician's guide. *J Am Coll Clin Pharm.* 2020;3:1333–1343.
- Martens T, Beck RW, and Bailey R. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin. *JAMA.* 2021;325(22):2262-72.
- Centers for Medicare & Medicaid Services. Glucose Monitor – Policy Article (A52464). Available from: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464>. Accessed March 22, 2024.
- South Dakota Department of Social Services. Continuous Glucose Monitor Coverage and Billing Changes. Available from: https://dss.sd.gov/docs/medicaid/providers/ProviderBulletins/2023/12.01.23_Continuous_Glucose_Monitor_Coverage_and_Billing_Changes.pdf. Accessed March 22, 2024.
- MN Department Of Human Services. Diabetic Equipment and Supplies. Available from: https://www.dhs.state.mn.us/main/idcplg?IdcService=GET_DYNAMIC_CONVERSION&RevisionSelectionMethod=LatestReleased&dDocName=DHS16_144501#cs. Accessed March 22, 2024.
- State of Iowa Department of Health and Human Services. Continuous Glucose Monitoring DME-006. Available from: <https://hhs.iowa.gov/media/311/download?inline=>. Accessed March 22, 2024.
- Nebraska Department of Health and Human Services. Nebraska Department of Health and Human Services Health Plan Advisory No. 20-22. Available from: <https://dhhs.ne.gov/Medicaid%20Health%20Plan%20Advisories/Health%20Plan%20Advisory%2022-02.pdf>. Accessed March 22, 2024.